◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
Polish Biotech Scene

BrainScan

AI head-CT diagnostics · Stroke / head-CT triage

Phase 3Seed / early-stageŁódźAI-Driven Drug Discovery
Focus / modality
AI head-CT diagnostics
Lead asset
BrainScan CT AI
Type
Diagnostics / AI
Indication
Stroke / head-CT triage
Stage
Phase 3
HQ
Łódź
Capital tier
Seed / early-stage
Backing
VC

Overview

AI that flags intracranial abnormalities (hemorrhage, stroke) on head CT to speed emergency triage.

What they do

BrainScan develops AI software that automatically analyses head CT scans, detecting and highlighting pathological changes to speed emergency triage. The flagship product, BrainScan CT, is designed to help radiologists and ER teams rapidly prioritise patients with intracranial abnormalities such as hemorrhage and stroke.

Lead program & status

BrainScan CT is a CE MDR 2017/745-certified medical device for AI-assisted interpretation of brain CT, reportedly identifying and classifying around 30 brain pathologies, with the company citing high accuracy for hemorrhage detection. It is also cleared for use in additional markets including the UK (MHRA) and Switzerland. In May 2024 BrainScan S.A. listed on the Warsaw Stock Exchange's NewConnect market under the ticker BSN. The company secured roughly EUR 2.6m from Poland's PARP under the SMART program for a multimodal brain-pathology diagnosis-support project running from 2025 into 2027.

Why it matters

In acute stroke and head trauma, minutes change outcomes. AI triage that surfaces likely hemorrhage or stroke first helps clinicians act faster, particularly where radiologist coverage is thin, making BrainScan's tool relevant to emergency workflows across hospital networks.

FAQ

Is BrainScan CT a certified medical device?
Yes. BrainScan CT holds CE certification under the EU MDR 2017/745 and is also approved in markets including the UK and Switzerland.
What does BrainScan CT detect?
It analyses head CT scans to detect and classify roughly 30 brain pathologies, including hemorrhage and stroke, to support faster triage.
Is BrainScan publicly traded?
Yes. BrainScan S.A. listed on the Warsaw Stock Exchange NewConnect market in May 2024 under the ticker BSN.

Technology

BrainScan works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.

Read the AI-Driven Drug Discovery brief →

Related companies

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.